Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP plus PD-1 inhibitor followed by local radiotherapy for de novo metastatic nasopharyngeal carcinoma
ChiCTR2300069086Phase 2Recruiting
- Sponsor
- Affiliated Cancer Hospital of Guangzhou Medical University
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by Affiliated Cancer Hospital of Guangzhou Medical University. Primary endpoint: Objective response rate. Started Jul 2022; status: recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2300069086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069086.